This is an observational study to evaluate the effectiveness of the truFreeze Cryotherapy System in patients who have been diagnosed with persistent local esophageal cancer and who are not candidates for surgery or have completed or declined systemic therapy. <br><br>The goal is to collect information on health related quality of life as well as additional tumor characteristics before and after cryotherapy.<br>
Be between 18 to 89 years of age
Have persistent esophageal cancer that is not eligible for surgery
Be able to tolerate an endoscopy procedure
Meet all other eligibility criteria
Have an esophageal stent
Be ineligible for an endoscopy or Spray Cryotherapy Procedure
Have had previous Spray Cryotherapy for esophageal cancer
Have received radiation within the past 6 weeks, or chemotherapy within the past 2 weeks
Have been in another clinical study within the past 6 weeks
Be pregnant, nursing, or planning to get pregnant during the study
The truFreeze® Cryotherapy System is approved by the FDA to treat esophageal cancer by delivering liquid nitrogen to the site of the cancer through an endoscopy procedure.
This study is for patients who are already planning to have spray cryotherapy for their esophageal cancer, and are having symptoms that may include difficulty swallowing, excessive weight loss, cough, chest pain, hoarseness, and vomiting.